The PrEP Access Act creates a new Medicare Part B benefit category for HIV prevention services furnished by pharmacists. It defines the covered services broadly to include counseling, screening, medication administration, and related clinical laboratory tests when the pharmacist is authorized by State law to provide them, and it extends Medicare’s no‑balance‑billing protections to pharmacists.
If enacted, the bill routes a set of prevention services into community pharmacies and other pharmacist settings — a structural change with consequences for access, payment mechanics, provider networks, and oversight. Compliance officers, pharmacy leaders, and Medicare program managers will need to sort out enrollment, coding, scope‑of‑practice variation across states, and how the new benefit intersects with existing physician‑led care pathways and lab billing rules.
At a Glance
What It Does
The bill adds a new definitional benefit under section 1861 of the Social Security Act that treats pharmacist‑provided HIV prevention services as Medicare Part B covered services when state law authorizes the pharmacist to furnish them. It also amends payment and billing statutes to set a specific payment formula for those services and to bar balance billing by pharmacists.
Who It Affects
The primary touchpoints are Medicare Part B beneficiaries at risk of HIV; pharmacists and community pharmacies that would enroll to bill Medicare; clinical laboratories that process related diagnostic tests; and Medicare contractors responsible for claims processing and provider enrollment. Physicians and clinics that currently deliver PrEP/PEP services will face a new channel for preventive care.
Why It Matters
This bill treats pharmacists as recognized Medicare providers for a preventive service class, which could substantially broaden access for older adults and disabled beneficiaries while setting a payment precedent for pharmacist‑delivered clinical services. The legislative language also creates immediate operational questions about coding, state scope‑of‑practice limits, and program integrity.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill creates a narrowly drawn Medicare benefit: ‘‘pharmacist‑provided HIV prevention services.’’ That phrase covers the same types of evaluation, counseling, medication administration, and related lab testing that Medicare would cover if a physician provided them — but only to the extent the pharmacist is legally authorized under state law to perform each task. The statute thus ties federal coverage to state scope‑of‑practice rules rather than rewriting state licensing law.
On the delivery side, the bill explicitly lists activities tied to HIV prevention: pre‑exposure prophylaxis (PrEP), post‑exposure prophylaxis (PEP), other evidence‑based prevention interventions, the administration of those medicines, and clinical diagnostic tests linked to those interventions. By allowing supplies and services ‘‘incident to’’ the pharmacist’s service, the text anticipates bundled encounters where the pharmacist handles counseling, orders or performs tests, and gives medication directly.The measure adjusts Medicare’s payment and billing framework for these encounters.
It inserts pharmacists into existing statutes that control how practitioners may bill beneficiaries (no balance billing) and preserves Medicare’s authority to deny payment for services it deems not ‘‘reasonable and necessary.’’ The bill therefore tries to expand access while keeping existing program safeguards and prohibitions in place.Practically, implementation will depend on administrative action. CMS and Medicare Administrative Contractors will have to decide how pharmacists enroll, what billing codes to use, how laboratories bill for diagnostics when pharmacists order testing, and how compliance will be monitored across states with varying pharmacist practice laws.
The statute sets coverage rules; operationalizing them will require guidance on claims processing, credentialing, and fraud detection.
The Five Things You Need to Know
The bill adds a new covered benefit defined in a new paragraph 1861(nnn): pharmacist‑provided HIV prevention services that are within a pharmacist’s state‑authorized scope and include PrEP, PEP, medication administration, counseling, and related lab tests.
It amends Medicare’s payment statute so that for these pharmacist services Medicare pays 80% of the lesser of (A) the pharmacist’s actual charge or (B) 85% of the amount that would be determined under the physician fee schedule (section 1848) for the service.
The bill extends Medicare’s prohibition on balance billing to pharmacists by amending section 1842(b)(18), meaning enrolled pharmacists may not bill beneficiaries above applicable Medicare payments for these services.
It adds a targeted exclusion to Medicare’s ‘‘reasonable and necessary’’ provision (section 1862(a)(1)) clarifying Medicare may deny payment for pharmacist HIV prevention services that it determines are not reasonable and necessary.
The coverage and statutory changes apply to items and services furnished on or after January 1, 2027.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Defines pharmacist‑provided HIV prevention services as a covered Part B benefit
The bill inserts pharmacist‑provided HIV prevention services into the list of items and services Medicare recognizes under section 1861. The new subsection 1861(nnn) ties coverage to services the pharmacist is legally authorized to provide under state law and lists categories of care — evaluation, management, screening, counseling, medication administration, and clinical diagnostic tests related to PrEP/PEP and other preventive interventions. Operationally, this approach makes federal coverage contingent on state scope‑of‑practice rules rather than creating new federal licensure; that will produce uneven coverage across states depending on what individual pharmacists are allowed to do locally.
Sets a specific payment rule for pharmacist‑delivered HIV prevention services
The bill amends the payment provision to require Medicare to pay 80% of the lesser of the pharmacist’s actual charge or 85% of the amount that would be payable under the physician fee schedule. This is a hybrid mechanism: it anchors payment to the physician fee schedule but caps it below that rate (85%) and also allows actual charges to control if lower. That structure will influence billing strategies (actual charge vs. fee schedule comparison), may create incentives around charge setting, and will require CMS to determine appropriate crosswalks between physician codes and pharmacist billing.
Prohibits balance billing by pharmacists for these services
Amendments add pharmacists into the statutory prohibition that prevents certain practitioners from charging beneficiaries above Medicare’s payment for services described as ‘‘incident to’’ practitioners’ services. For pharmacists, this means accepted Medicare billing rules (and the penalties for improper balance billing) will apply, removing the option to seek supplemental payment directly from beneficiaries for covered pharmacist HIV prevention services.
Preserves Medicare’s ability to deny non‑reasonable or necessary services
The bill inserts a new subparagraph permitting Medicare to refuse payment when pharmacist‑provided HIV prevention services are not ‘‘reasonable and necessary’’ for prevention or detection. That mirrors existing Medicare authority and gives CMS a statutory hook to set clinical standards or to deny payments that lack documentation or clinical justification.
Effective date
The statute states the amendments apply to items and services furnished on or after January 1, 2027. That creates a clear compliance deadline for enrollment and operational changes by pharmacies, but it also compresses the time CMS and MACs will have to issue interpretive guidance, update claims systems, and coordinate with state boards of pharmacy.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medicare beneficiaries at risk of HIV: The change makes it easier for seniors and disabled beneficiaries to access PrEP/PEP and related services in community settings, reducing travel and referral barriers.
- Community pharmacies and pharmacists: Pharmacists gain a new billable service line and formal recognition in Medicare for delivering prevention services, creating potential revenue and expanding clinical roles.
- Public health programs and payers: Wider access to prevention in pharmacies can raise uptake of PrEP/PEP and related testing among populations that underuse traditional clinician settings, which may reduce downstream HIV diagnoses and treatment costs.
- Clinical laboratories offering HIV‑related diagnostics: Labs that can accept orders from pharmacists could see increased test volumes tied to pharmacy‑based screening and monitoring.
Who Bears the Cost
- Medicare program and trust funds: Expanding a covered preventive benefit and introducing new billing pathways will increase program expenditures, at least initially, for testing and medication administration.
- Pharmacies and pharmacists (compliance costs): Pharmacies must invest in training, documentation systems, CLIA compliance for point‑of‑care tests where applicable, and potentially new liability coverage to meet Medicare enrollment and oversight requirements.
- CMS and Medicare Administrative Contractors: Administrators must write guidance, update claims systems, manage provider enrollment and credentialing for pharmacists, and monitor program integrity — tasks that require staff time and budget.
- Physician practices that currently deliver PrEP/PEP: Some practices may see lower visit volumes for prevention services as patients shift to pharmacies, creating revenue and care‑coordination impacts.
Key Issues
The Core Tension
The central dilemma is accessibility versus clinical governance: the bill expands access by empowering pharmacists to deliver prevention services in convenient settings, but doing so reduces the built‑in clinical oversight that physician‑led models provide and creates disparate service availability across states; policy makers must balance increased preventive reach against risks to care continuity, quality standards, and program spending.
The bill deliberately anchors federal coverage to state authorization, which preserves state control over pharmacist scope but also guarantees inconsistent national access. In states where pharmacists already have authority to initiate PrEP/PEP and order tests, the benefit will fall into place; in more restrictive states, the federal law creates a coverage promise that many pharmacists cannot fulfill.
That tension will complicate CMS guidance and lead to patchwork service availability nationwide.
The payment formula is unusual: tying Medicare payment to 85% of a physician‑based amount while paying beneficiaries 80% of the lesser of actual charge or that cap creates multiple behavioral levers. Pharmacies may price actual charges strategically, and CMS will need to decide how to map pharmacist services to physician fee schedule codes for payment comparisons.
The statute also leaves open operational questions about enrollment (can a pharmacist bill directly, or must a supervising entity enroll?), test ordering and lab billing (HIPAA/CLIA and payer rules), and how ‘‘incident to’’ language will be interpreted in practice. Finally, program integrity and clinical quality concerns — who documents clinical decision‑making, how adverse events are reported, and how coordinative care with primary clinicians is maintained — are not resolved in the text.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.